Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indinavir, Efavirenz, and Adefovir Dipivoxil Combination Therapy in HIV
NCT00002220Phase 3Completed
- Sponsor
- Merck & Co.
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of efavirenz in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Merck & Co. Primary endpoint: Proportion of patients with viral load below 400 copies/ml at 48 weeks. Status: completed.
02
Drugs
efavirenz
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00002220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002220.